Ibrutinib Treatment In Waldenström Macroglobulinemia Waldenström macroglobulinemia (WM) is a rare type of non-hogdkins lymphoma driven by the gene mutation MYD88L265P. Ibrutinib, the first approved treatment, is effective but can cause side effects. A study found that 27% of WM patients needed to reduce Ibrutinib doses due to side effects like
Tag: lymph
